TrialBMC pulmonary medicine2018

Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial.

Pablo Altman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.